Study of HH2853 for relapsed or refractory peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these types of T-cell lymphoma: PTCL-NOS, AITL, ALK+ ALCL, ALK- ALCL, NKTCL, enteropathy-associated T-cell lymphoma, or others as listed.
- Your lymphoma has come back or not responded after at least one prior treatment (and usually no more than 4 to 5 previous treatments).
- You can perform daily activities without help (ECOG score 0 or 1).
- Your organs (bone marrow, liver, kidneys) are working well enough, as shown by blood tests.
- You must provide a tissue sample from a biopsy for central lab testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
Hear when a new Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.